HYSR 10-K & 10-Q changes, risk factors and insider trading
Sunhydrogen, Inc. · OTC · Semiconductors & Related Devices · CIK 1481028 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
New heading “We have generated no revenue from the sale of our products, we have incurred losses since inception, and we may never become profitable.”
New heading “We will require substantial additional capital, and the equity purchase agreement that had been our principal source of funding expired during the fiscal year.”
New heading “We depend on a small management team and limited administrative resources, and our internal resources may be insufficient as our operations become more complex.”
New heading “We have not produced hydrogen at commercial scale, and we may never do so.”
New heading “We may never achieve our cost goal, and the improvements required to do so depend substantially on factors outside our control.”
New heading “Our pilot program may not be completed on schedule, and its results may not predict commercial performance.”
New heading “We have not determined how we will generate revenue, and the model we ultimately adopt may prove unprofitable.”
New heading “Demand for our potential products will depend on the adoption of renewable hydrogen, which has been slower than anticipated.”
New heading “We may not be able to have our products manufactured at commercial volumes, cost, or quality.”
New heading “Risks related to our partners, suppliers, and operations”
New heading “Our joint development agreement with Honda R&D Co., Ltd. has expired and may not be extended.”
New heading “We depend on a small number of third parties for essential development, manufacturing, and testing functions, and the loss of any of them could delay our program.”
New heading “Our operations in Austria and Japan expose us to risks we have not previously faced.”
New heading “Our supply chain depends on materials that are geographically concentrated and produced in limited quantities.”
New heading “Our insurance coverage is limited, and an uninsured loss or liability could be material to us.”
New heading “Our business could be harmed by a cybersecurity incident.”
New heading “Risks related to our intellectual property”
New heading “Our patents may not protect our technology, and much of what we rely on is not patented.”
New heading “Certain of our patents are jointly owned, which limits our ability to enforce them.”
New heading “We may infringe the intellectual property rights of others, and we have not completed an infringement analysis.”
New heading “Risks related to regulation, incentives, and safety”
New heading “The principal federal incentive for clean hydrogen production may not be available for our technology, which could make our products less attractive to customers and impair our ability to compete on cost.”
New heading “Reductions in government support for renewable hydrogen may slow industry growth and adversely affect our opportunities.”
New heading “Our products will require permits and approvals we have not obtained, and our operations are subject to environmental and safety regulation.”
New heading “Hydrogen is flammable, and an incident during our development activities could expose us to liability and delay our program.”
New heading “Risks related to our common stock”
New heading “Conversion of our outstanding preferred stock and exercise of outstanding warrants and options will dilute holders of our common stock.”
New heading “We expect to issue additional securities to fund our operations, which will further dilute our stockholders.”
New heading “We have never paid dividends and do not intend to, so any return on your investment depends on appreciation in our stock price.”
New heading “We are a smaller reporting company and provide reduced disclosure, which may make our common stock less attractive to some investors.”
Removed heading “Our limited operating history does not afford investors a sufficient history on which to base an investment decision.”
Removed heading “We have a history of losses and have never realized revenues to date. We expect to continue to incur losses and no assurance can be given that we will realize revenues. Accordingly, we may never achieve and sustain profitability.”
Removed heading “We may be unable to manage our growth or implement our expansion strategy.”
Removed heading “We may not be able to successfully develop and commercialize our technologies which would result in continued losses and may require us to curtail or cease operations.”
Removed heading “Our revenues will be dependent upon acceptance of our products by the market, the failure of which would cause us to curtail or cease operations.”
Removed heading “We anticipate that we will face intense competition, and many of our competitors have substantially greater resources than we do.”
Removed heading “Because our industry is highly competitive and has low barriers to entry, we may lose market share to larger companies that are better equipped to weather a deterioration in market conditions due to increased competition.”
Removed heading “Reductions in U.S. federal funding for renewable hydrogen projects may slow industry growth and could adversely affect our long-term opportunities.”
Removed heading “Our business depends on proprietary technology that we may not be able to protect and may infringe on the intellectual property rights of others.”
Removed heading “We do not maintain theft or casualty insurance and only maintain liability and property insurance coverage and therefore, we could incur losses as a result of an uninsured loss.”
Removed heading “If we lose key employees and consultants or are unable to attract or retain qualified personnel, our business could suffer.”
Removed heading “The loss of strategic alliances used in the development of our products and technology could impede our ability to complete our product and result in a material adverse effect causing the business to suffer.”
Removed heading “Our common stock could be subject to extreme volatility.”
Removed heading “We anticipate that our issuance of common stock upon conversion of Series C Preferred Stock, exercise of outstanding warrants and options, will result in dilution to our stockholders.”
Removed heading “We have never paid common stock dividends and have no plans to pay dividends in the future, as a result our common stock may be less valuable because a return on an investor’s investment will only occur if our stock price appreciates.”
Removed heading “Additional stock offerings in the future may dilute then-existing shareholders’ percentage ownership of the Company.”
Largest changes
“Our common stock is subject to the Securities and Exchange Commission’s penny stock rules, which apply to equity securities that are not listed on a national securities exchange and that do not satisfy specified price or financial thresholds. Under these rules, a broker-dealer must deliver a standardized risk disclosure document before effecting a transaction, make a suitability determination for the customer, obtain the customer’s written consent, and provide monthly account statements. …”see in full comparison
“Because our industry is highly competitive and has low barriers to entry, we may lose market share to larger companies that are better equipped to weather a deterioration in market conditions due to increased competition.”see in full comparison
“Our business could be harmed by a cybersecurity incident.”see in full comparison
“Our products will require permits and approvals we have not obtained, and our operations are subject to environmental and safety regulation.”see in full comparison
“We anticipate that we will face intense competition, and many of our competitors have substantially greater resources than we do.”see in full comparison
“Our supply chain depends on materials that are geographically concentrated and produced in limited quantities.”see in full comparison
Full comparison: every changed paragraph (111)
An investment in our common stock involves a high degree of risk. You should carefully consider the following risks, together with the other information in this report, before deciding to invest. Our business, financial condition, and results of operations could be materially and adversely affected as a result of these risks, and you could lose all or part of your investment. The risks described below are not the only ones we face, and additional risks not presently known to us, or that we currently consider immaterial, may also impair our business.
Risks related to our businessfinancial condition and industryneed for capital
We have generated no revenue from the sale of our products, we have incurred losses since inception, and we may never become profitable.
We were formed in February 2009 and have not generated any revenue from the sale of our products. We recognized $1,250 of revenue during the fiscal year ended June 30, 2026 from consulting services provided to a related party, and no revenue in the prior fiscal year. As of June 30, 2026 we had an accumulated deficit of $106,633,674, and we incurred a net loss of $6,555,124 for the fiscal year then ended. Our accumulated deficit includes significant non-cash charges, including charges related to convertible notes issued in prior years and stock-based compensation, and is therefore substantially greater than the amount of cash we have used in operations since inception. We expect to continue to incur losses until we are able to generate revenue sufficient to fund our operations, and we may never do so. We have no products available for sale, no customers, and no agreements that would generate revenue. Even if we complete development of our technology, we may never achieve or sustain profitability.
We will require substantial additional capital, and the equity purchase agreement that had been our principal source of funding expired during the fiscal year.
We have funded our operations primarily through sales of equity securities, principally under an equity purchase agreement with GHS Investments, LLC, , that expired on June 3, 2026 in accordance with its terms. We do not currently have a committed source of additional capital. We will require additional capital to continue developing our technology, to complete our pilot program, and to reach commercial production. Additional capital may not be available on acceptable terms or at all, particularly given our stage of development, the absence of revenue, and conditions in the hydrogen sector. If we cannot raise capital when needed, we may be required to delay, reduce, or eliminate development programs, and we may be unable to continue operating. Any financing we do obtain is likely to dilute existing stockholders, and debt financing, if available, may impose covenants restricting our operations.
We depend on a small management team and limited administrative resources, and our internal resources may be insufficient as our operations become more complex.
We had 12 full-time employees as of September 18, 2026, operating across facilities in Iowa, Austria, and Japan, and we rely on consultants and contract personnel for functions many companies perform internally. Our Chief Executive Officer also serves as our Acting Chief Financial Officer. As we advance our pilot program, add foreign subsidiaries, and expand our partner relationships, the demands on our administrative, operational, and financial reporting functions will increase. If we are unable to recruit and retain necessary personnel or to establish and maintain adequate operating and financial controls, our development timeline, our financial reporting, and our results of operations could be materially and adversely affected.
Our limited operating history does not afford
investors a sufficient history on which to base an investment decision.
We were formed in February
2009 and are currently developing a new technology that has not yet gained market acceptance. There can be no assurance that we will ever
commercialize our technology, operate profitably or that we will have adequate working capital to meet our obligations as they become
due.
Investors must consider the
risks and difficulties frequently encountered by early-stage companies, particularly in rapidly evolving markets. Such risks include the
following:
We cannot be certain that
our business strategy will be successful or that we will successfully address these risks. In the event that we do not successfully address
these risks, our business, prospects, financial condition, and results of operations could be materially and adversely affected, and we
may have to curtail our business.
We have a history of losses and have never
realized revenues to date. We expect to continue to incur losses and no assurance can be given that we will realize revenues. Accordingly,
we may never achieve and sustain profitability.
As of June 30, 2025, we have
an accumulated deficit of $100,078,550. For the year ended June 30, 2025, we incurred a net loss of $8,226,307. We expect to incur net
losses until we are able to realize revenues to fund our continuing operations. We may fail to achieve any or significant revenues from
sales or achieve or sustain profitability. Accordingly, we may never be profitable or be able to maintain profitability.
We have historically raised
funds through various capital raising transactions. We will require additional funds in the future to fund our business plans, either
through additional equity or debt financings or collaborative agreements or from other sources. We have no commitments to obtain such
additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. In the event
we are unable to obtain additional financing, we may be unable to implement our business plan. Even with such financing, we have a history
of operating losses and there can be no assurance that we will ever become profitable.
We may be unable to manage our growth or
implement our expansion strategy.
We may not be able to develop
our product or implement the other features of our business strategy at the rate or to the extent presently planned. Our potential growth
will place a significant strain on our administrative, operational and financial resources. If we are unable to successfully manage our
future growth, establish and continue to upgrade our operating and financial control systems, recruit and hire necessary personnel or
effectively manage unexpected expansion difficulties, our financial condition and results of operations could be materially and adversely
affected.
We may not be able to successfully develop
and commercialize our technologies which would result in continued losses and may require us to curtail or cease operations.
We are currently working to
scale the lab-scale prototypes of our nanoparticle technology to larger, commercial-scale prototypes. However, we have not completed a
large-scale commercial prototype of our technology and are uncertain at this time when completion of a commercial scale prototype will
occur. We may be unable to commercialize our technology.
Our revenues will be dependent upon acceptance
of our products by the market, the failure of which would cause us to curtail or cease operations.
We believe that virtually
all of our revenues will come from the sale or license of our products. As a result, we will continue to incur substantial operating losses
until such time as we are able to develop our product and generate revenues from the sale or license of our products. There can be no
assurance that businesses and customers will adopt our technology and products, or that businesses and prospective customers will agree
to pay for or license our products. Even if we complete development of our technology and product, , it may not gain market acceptance
due to various factors such as not enough cost savings between our method of producing hydrogen and other more conventional methods. If
that occurs, our financial condition and results of operations will be materially and adversely affected.
We anticipate that we will face intense
competition, and many of our competitors have substantially greater resources than we do.
We operate in a competitive
environment that is characterized by price fluctuation and technological change. We anticipate that we will compete with major international
and domestic companies. Some of our current and future potential competitors may have greater market recognition and customer bases, longer
operating histories and substantially greater financial, technical, marketing, distribution, purchasing, manufacturing, personnel and
other resources than we do. In addition, competitors may be developing similar technologies with a cost similar to, or lower than, our
projected costs. As a result, they may be able to respond more quickly to changing customer demands or to devote greater resources to
the development, promotion and sales of solar and solar-related products than we can.
Our business plan relies on
sales of our products based on either a demand for truly renewable clean hydrogen or economically produced clean hydrogen. If we fail
to compete successfully, our business would suffer and we may lose or be unable to gain market share. Neither the demand for our product
nor our ability to manufacture at commercial scale have yet been proven.
Because our industry is highly competitive
and has low barriers to entry, we may lose market share to larger companies that are better equipped to weather a deterioration in market
conditions due to increased competition.
We believe that our ability
to compete depends in part on a number of factors outside of our control, including:
Currently, competing methods
of hydrogen production include steam reforming of natural gas or methane, which dominates due to its easy availability and low price;
partial oxidation of petroleum oil; steam gasification of coal; and electrolyzers powered by solar or wind energy. There can be no assurance
that we will be able to compete successfully against current and future competitors. If we are unable to compete effectively, or if competition
results in a deterioration of market conditions, our business and results of operations would be adversely affected.
Reductions in U.S. federal funding for renewable hydrogen projects
may slow industry growth and could adversely affect our long-term opportunities.
In 2025, the U.S. Department of Energy (DOE) reduced
certain funding allocations for renewable hydrogen development. While we currently have sufficient capital to carry on our operations
and advance our technology development, these changes may slow overall industry momentum in the United States by limiting the pace of
project development, infrastructure buildout, and adoption of hydrogen technologies. A slower rate of industry expansion could, in turn,
impact the timing and scale of potential commercial opportunities available to us in the U.S. market. Although we continue to pursue growth
through our own resources and potential partnerships, reduced government support could adversely affect the broader competitive landscape
and may negatively influence investor and customer interest in renewable hydrogen solutions.
Our business depends on proprietary
technology that we may not be able to protect and may infringe on the intellectual property rights of others.
Our success will depend, in
part, on our technology’s commercial viability and on the strength of our intellectual property rights. We currently hold patents
in the US, China, Australia, and Europe but still have several patents pending in multiple countries. There is no guarantee the
pending patents will be granted. In addition, any agreements we enter into with our employees, consultants, advisors, customers and strategic
partners will contain restrictions on the disclosure and use of trade secrets, inventions and confidential information relating to our
technology may not provide meaningful protection in the event of unauthorized use or disclosure.
Third parties may assert that
our technology, or the products we, our customers or partners commercialize using our technology, infringes upon their proprietary rights.
We have yet to complete an infringement analysis and, even if such an analysis were available at the current time, it is virtually impossible
for us to be certain that no infringement exists, particularly in our case where our products have not yet been fully developed.
We may need to acquire licenses
from third parties in order to avoid infringement. Any required license may not be available to us on acceptable terms, or at all.
We could incur substantial
costs in defending ourselves in suits brought against us for alleged infringement of another party’s intellectual property rights
as well as in enforcing our rights against others, and if we are found to infringe, the manufacture, sale and use of our or our customers’
or partners’ products could be enjoined. Any claims against us, with or without merit, would likely be time-consuming, requiring
our management team to dedicate substantial time to addressing the issues presented. Furthermore, the parties bringing claims may have
greater resources than we do.
We do not maintain theft or casualty insurance
and only maintain liability and property insurance coverage and therefore, we could incur losses as a result of an uninsured loss.
We do not maintain theft,
casualty insurance, or property insurance coverage. We may incur uninsured liabilities and losses as a result of the conduct of our business.
Any such uninsured or insured loss or liability could have a material adverse effect on our results of operations.
If we lose key employees and consultants
or are unable to attract or retain qualified personnel, our business could suffer.
Our success is highly dependent
on our ability to attract and retain qualified scientific, engineering and management personnel. We are highly dependent on our Chief
Technical Officer, Dr. Syed Mubeen, our development team in Iowa and our industrial partners and vendors. There can be no assurance
that they will remain associated with us. Our management’s efforts will be critical to us as we continue to develop our technology
and as we attempt to transition from a development stage company to a company with commercialized products and services. If we were to
lose Dr. Mubeen, one of our development partners, any other key employees or consultants, we may experience difficulties in competing
effectively, developing our technology and implementing our business strategies.
The loss of strategic alliances used in
the development of our products and technology could impede our ability to complete our product and result in a material adverse effect
causing the business to suffer.
We pursue strategic alliances
with other companies in areas where collaboration can produce technological and industry advancement. For example, we have entered into
a sponsored research agreement with the University of Michigan which, which was extended through September 30, 2026. If we are unable
to extend the terms of this agreement, or any of our other agreements with our partners as described in this report, we could suffer delays
in product development or other operational difficulties which could have a material adverse effect on our results of operations.
Risks relatingrelated to our commontechnology stockand product development
We have not produced hydrogen at commercial scale, and we may never do so.
We are developing two pathways to photoelectrochemical hydrogen production. Our thin film pathway has produced hydrogen reactors measuring 1.92 square meters, and our nanoparticle pathway remains at laboratory scale. Neither pathway has produced hydrogen at commercial scale or over a commercially relevant operating lifetime. Scaling a photoelectrochemical device involves engineering challenges that do not arise at laboratory scale, including uniformity of coatings over large areas, separation and collection of hydrogen and oxygen, corrosion of active surfaces in contact with water over extended periods, and maintenance of efficiency as area increases. We may be unable to solve these problems, and we cannot predict when, or whether, we will complete a commercial scale system.
We may never achieve our cost goal, and the improvements required to do so depend substantially on factors outside our control.
Our goal is to produce renewable hydrogen at a cost of $2.50 per kilogram. Techno-economic modeling prepared with Strategic Analysis, Inc. currently projects a production cost of approximately $4 to $5 per kilogram at commercial scale, before the benefit of any tax credits. Closing that difference will require improvements in the solar-to-hydrogen conversion efficiency of our devices, in the operating lifetime of our panels, in our manufacturing yield and scale, in the substitution of catalysts based on earth-abundant materials for those incorporating precious metals, in the cost of substrates, semiconductor materials, coatings, and balance of system components, and in the cost and energy consumption of hydrogen compression equipment. Many of these depend on the continued advancement of the solar photovoltaic industry and of hydrogen handling technology rather than on our own development work, and we cannot influence the pace of that advancement.
In addition, the prices of glass, tellurium, and precious metals have historically been volatile, tariffs and other trade measures have affected the cost and availability of photovoltaic modules and components, and the operating lifetime of our panels under field conditions has not been established. Our projected cost also depends on assumptions regarding production volume, capital cost, insolation, and panel lifetime that may prove incorrect. We have not demonstrated any of these improvements at commercial scale. If they are not achieved, or if costs move adversely, we may never produce hydrogen at a cost competitive with hydrogen produced from fossil fuels, and we may be unable to sell our potential products profitably or at all.
Our pilot program may not be completed on schedule, and its results may not predict commercial performance.
We are developing a pilot hydrogen production system at the University of Texas at Austin’s Center for Electromechanics, a facility we do not own or control. We intend to have sixteen hydrogen reactors operating at that site by December 31, 2026, and we may not achieve that schedule. The system may not achieve the conversion efficiency, operating availability, or hydrogen purity we expect, and gas separation and hydrogen purity have been identified in our own engineering analysis as significant technical risks. Because we depend on a third party’s facility, we are also exposed to changes in that institution’s priorities, personnel, and site access. Results obtained at pilot scale may not be indicative of performance at commercial scale, and unfavorable results could delay our development program, impair our ability to raise capital, and adversely affect our relationships with partners and potential customers.
We have not determined how we will generate revenue, and the model we ultimately adopt may prove unprofitable.
We have not determined whether we will sell hydrogen panels, sell hydrogen produced by systems we own or operate, license our technology, or pursue some combination of these approaches. Each model carries different capital requirements, operating risks, and time to revenue. Selling hydrogen would require substantially more capital than selling panels, because we would need to fund the construction, ownership, and operation of production facilities, and would expose us to permitting requirements, site development risk, and the need to secure offtake contracts on acceptable terms. Licensing would reduce our capital requirements but would also reduce the revenue we retain and would make us dependent on the performance of licensees. We may adopt a model that proves unprofitable, or we may change models after committing capital, and either outcome could materially and adversely affect our business.
Demand for our potential products will depend on the adoption of renewable hydrogen, which has been slower than anticipated.
Our potential products will have value only if buyers are willing to pay for renewable hydrogen or for equipment that produces it. According to the International Energy Agency, low emissions hydrogen accounted for slightly more than one percent of global hydrogen production in 2026, announced government production targets for 2030 substantially exceed the capacity of projects that have secured investment decisions, and production from unabated fossil fuels is expected to remain less costly than renewable hydrogen in most regions in the near term. Adoption depends on government policy, natural gas prices, the cost of competing technologies, and the willingness of industrial buyers to pay a premium for lower emissions hydrogen, none of which we control. If renewable hydrogen is adopted more slowly than we expect, or if buyers will not pay a premium, demand for our potential products may not develop.
We may not be able to have our products manufactured at commercial volumes, cost, or quality.
Our thin film pathway is designed to be manufactured on existing solar production lines, and we rely on third parties for module fabrication and for coating and catalyst processes. We have not manufactured at commercial volume, and we have not established that our processes can be operated at commercial yield. Manufacturing photoelectrochemical devices requires process control beyond that required for conventional photovoltaic modules, including repeatability of catalyst and protective coatings across large areas, which our own engineering analysis has identified as a significant risk. If we cannot achieve acceptable yields, or if our manufacturing partners are unable or unwilling to produce our products at the volumes, cost, or quality we require, our commercialization would be delayed and our costs would increase.
Risks related to our partners, suppliers, and operations
Our joint development agreement with Honda R&D Co., Ltd. has expired and may not be extended.
Our joint development agreement with Honda R&D Co., Ltd. expires on March 31, 2028. Honda has served as our housing unit and balance of system partner and has performed third-party validation testing of our hydrogen modules. If the relationship is not continued, we may lose access to that expertise and testing capability and may be required to identify alternative partners or perform the work ourselves, either of which could delay our development program and increase our costs. In addition, intellectual property developed in collaboration with Honda is subject to allocation provisions, and any dispute regarding ownership of jointly developed intellectual property could be costly and could adversely affect our rights.
We depend on a small number of third parties for essential development, manufacturing, and testing functions, and the loss of any of them could delay our program.
We conduct much of our development through relationships with third parties, including CTF Solar GmbH for thin film module fabrication, the University of Iowa and the University of Michigan under sponsored research agreements, the University of Texas at Austin’s Center for Electromechanics for our pilot facility, Sparc Hydrogen Pty Ltd for testing and evaluation, and other partners and consultants described in Item 1. Our sponsored research agreement with the University of Michigan expires on September 30, 2026. We are reviewing a possible extension and may be unable to agree on one. These arrangements are generally terminable or of limited duration, most of these parties are not obligated to work exclusively with us, and we have limited ability to control their priorities, resources, or timing. The loss of any of these relationships, or a failure to renew them on acceptable terms, could delay our development program, increase our costs, and require us to develop internal capabilities we do not currently possess.
Our operations in Austria and Japan expose us to risks we have not previously faced.
Management's Discussion & Analysis (MD&A)
New heading “Forward-Looking Statements”
Largest changes
“Forward-looking statements in this report should be read together with the risks described under Item 1A, Risk Factors, and with the other information in this report. Subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by those risks and by the cautionary statements in this report and in our other filings with the Securities and Exchange Commission. …”see in full comparison
“We believe renewable hydrogen has already proven itself to be a key solution in helping the world meet climate targets, and we believe our technology potentially offers solutions to the challenges that the hydrogen future presents, including cost of production and transportation.”see in full comparison
“Our technology is primarily developed at three laboratories - our independent laboratory in Coralville, Iowa, the SunHydrogen laboratory at the University of Iowa, and the Singh laboratory at University of Michigan.”see in full comparison
“Forward-looking statements present our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. …”see in full comparison
“Certain statements in this Annual Report are not historical facts and are forward-looking statements. Forward-looking statements present our expectations or forecasts of future events, and can often be identified by words such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of those terms. These statements involve known and unknown risks and uncertainties that may cause our actual results to differ materially from those expressed or implied. …”see in full comparison
Full comparison: every changed paragraph (28)
Forward-Looking Statements
Certain statements in this Annual Report are not historical facts and are forward-looking statements. Forward-looking statements present our expectations or forecasts of future events, and can often be identified by words such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of those terms. These statements involve known and unknown risks and uncertainties that may cause our actual results to differ materially from those expressed or implied. Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements, or the timing of any of them.
Forward-looking statements in this report should be read together with the risks described under Item 1A, Risk Factors, and with the other information in this report. Subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by those risks and by the cautionary statements in this report and in our other filings with the Securities and Exchange Commission. We disclaim any obligation to update any forward-looking statement, or to disclose any difference between our actual results and those reflected in any forward-looking statement, except as required by law.
Certain statements in “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” below, and elsewhere in this annual report, are not related
to historical results, and are forward-looking statements.
Forward-looking statements
present our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly
to historical or current facts. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance
or achievements expressed or implied by such forward-looking statements. Forward-looking statements frequently are accompanied by such
words such as “may,” “will,” “should,” “could,” “expects,” “plans,”
“intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential”
or “continue,” or the negative of such terms or other words and terms of similar meaning. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements,
or timeliness of such results. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such
forward-looking statements. We disclaim any obligation to publicly update these statements, or disclose any difference between actual
results and those reflected in these statements, except as may be required under applicable law.
Subsequent written and oral
forward looking statements attributable to us or to persons acting in our behalf are expressly qualified in their entirety by the cautionary
statements and risk factors set forth below and elsewhere in this annual report, and in other reports filed by us with the SEC.
You should read the following
description of our financial condition and results of operations in conjunction with the financial statements and accompanying notes included
in this Annual Report beginning on page F-1.
We are a development stage company and have not generated significant revenue since our inception in February 2009. Our operating expenses consist primarily of research and development expenses and general and administrative expenses. We have funded our operations principally through sales of our equity securities and expect to continue to do so. For a description of our business, our technology, our development programs, and the risks we face, see Item 1, Business, and Item 1A, Risk Factors.
You should read the following discussion of our financial condition and results of operations together with our financial statements and the accompanying notes included in this Annual Report beginning on page F-1.
At
SunHydrogen, our goal is to replace fossil fuels with clean, renewable hydrogen.
Hydrogen
is the most abundant chemical element in the universe. When hydrogen fuel is used to power transportation and industry, the only byproduct
left behind is pure water, unlike hydrocarbon fuels such as oil, coal and natural gas that emit carbon dioxide and other harmful pollutants
into the atmosphere. However, naturally occurring elemental hydrogen is rare - so rare, in fact, that today about 95% of hydrogen is produced
from steam reforming of natural gas (Source: US Department of Energy, Hydrogen Fuel Basics). This process is both economically
and environmentally unsound.
The
SunHydrogen solution offers an efficient and cost-effective way to produce truly renewable hydrogen using sunlight and any source of water.
Our core technology is a self-contained, nanoparticle-based hydrogen generator that mimics photosynthesis to split water molecules, resulting
in hydrogen. By optimizing the science of water electrolysis at the nano-level, we believe we have developed a low-cost method to potentially
produce environmentally friendly renewable hydrogen.
We
believe renewable hydrogen has already proven itself to be a key solution in helping the world meet climate targets, and we believe our
technology potentially offers solutions to the challenges that the hydrogen future presents, including cost of production and transportation.
Because
our process only requires sunlight and water, our technology can be installed near the point of hydrogen use. This eliminates the need
for pipelines and trucks that result in high carbon emissions and high capital investment. Additionally, because our process directly
uses the electrical charges created by sunlight to generate hydrogen, our nanoparticle technology does not rely on grid power or require
the costly power electronics that conventional electrolyzers do. Lastly, our planned scalable system configuration of many individual
hydrogen-generating panels ensures redundancy, security and stability.
With
a target cost of $2.50/kg., we aspire for our technology to be cost-competitive with brown hydrogen and below the cost of clean hydrogen
competitors. We believe our solution has the potential to clear a path for renewable hydrogen to compete with natural gas hydrogen and
gain mass market acceptance as a true replacement for fossil fuels.
Our
technology is primarily developed at three laboratories - our independent laboratory in Coralville, Iowa, the SunHydrogen laboratory at
the University of Iowa, and the Singh laboratory at University of Michigan.
Additionally,
in parallel to the ongoing development of our own technology, we may begin pursuing synergistic strategic investments in the hydrogen
space. SunHydrogen is committed to furthering renewable hydrogen technology to grow the hydrogen ecosystem, and we are actively pursuing
opportunities for investment and acquisition of complimentary hydrogen technologies.
Revenues
Revenues for the year ended June 30, 2026 were $1,250, compared to $0 for the year ended June 30, 2025. The net change of $1,250 in revenue was due to the Company providing consulting services to a related party during the year ended June 30, 2026 with no similar consulting services provided in the prior year.
For the year ended June 30, 2025,2026, operating expenses
were $5,816,192$7,521,904 compared to $5,001,300,$5,816,192, for the year ended June 30, 2024.2025. Operating expenses consist primarily of research and development
expenses and general and administrative expenses incurred in connection with the operation of our business. The increase of $814,892$1,704,462 in
operating expenses was primarily due to an increase in salary expenses andexpenses, an increase in research and development costs offsetand byan aincrease decrease
in professionalselling fees.and marketing costs.
Other income and (expenses) for the year ended
June 30, 2025,2026, were $(2,410,115)$898,130 compared to $(4,879,9032,410,115) for the year ended June 30, 2024.2025. The net increase of $2,469,788$3,399,245 in other income
and (expenses) was mainly the result of a decrease in dividend expense of $37,506, a decrease in unrealized loss on related party equity investments
of $2,592,099, a decrease in realized loss of $172,440, an increase in unrealized loss onthe change in fair value of short-terminvestments, investments
$30,615,related and a decrease in interest expenseparty of $3,932$4,101,402, offset by a decrease in investment income of $276,558, a decrease in capital gain
on sale of vehicle of $55,166,$496,390, and a decrease in realizedunrealized gain on redemptionchange in fair value of marketableshort-term securitiesinvestments of $35,080.$331,965.
For the year ended June 30, 2026, our net loss was $6,531,524, compared to a net loss of $8,226,307 for the year ended June 30, 2025. The majority of the decrease in net loss of $1,694,783, was primarily due to the unrealized loss on the Company’s investment in TECO (Equity securities, related party on the Consolidated Balance Sheets) in the prior period compared to no unrealized loss on the Company’s investment in TECO the current year. In addition, the Company generated minimal revenues in the current year and none in the prior year period and had a large increase in operating expenses in the current year compared to the prior year period due to increased efforts in operations as explained above.
For the year ended June 30,
2025, our net loss was $8,226,307, compared to a net loss of $9,881,203 for the year ended June 30, 2024. The majority of the decrease
in net loss of $1,654,896, was related primarily to the decrease in other income (expenses) offset by the increase in operating expenses
as explained above.
As of June 30, 2025,2026, we had
a working capital surplus of $37,048,679,$31,819,205, compared to a working capital surplus of $42,386,683$37,048,679 as of June 30, 2024.2025. This decrease in working
capital surplus of $5,338,004$5,229,474 was primarily due to a decrease in cash and equity securities, related party offset by an increaseincreases in prepaids, note receivable, interest receivable, short-term
investments. investments, and total current liabilities.
Cash flow used in operating
activities was $5,065,357 for the year ended June 30 2026, compared to $3,647,278 for the year ended June 30 2025, compared to $1,842,726 for the year ended June 30, 2024.2025. The increase of $1,804,552
$1,418,079 in cash used by operating activities was primarily due to a $1,671,183 decrease in non-cashnet expenses,loss, ana increasechange of $15,438 in prepaid expenses, othera receivables,
andchange accruedof expenses,$7,709 andin decreaseinterest receivable, a change of $24,364 in accounts payable.payable Theand a change of $132,525 in accrued expenses offset by a change of $3,290,605 in non-cash expenses. In addition, the Company had nominimal revenues during the yearsyear ended June 30, 20252026 andcompared 2024.to none for the year ended June, 30, 2025.
Cash provided by (used in)
investing activities for the year ended June 30, 20252026 was $(2,924,98817,200,794), compared to $2,920,237$(2,924,988) for the year ended June 30, 2024.2025. The decrease
increase of $5,845,225$14,275,806 in cash provided by (used in) investing activities was due to the change in net purchase of short-term investments of $2,907,988$18,159,385 and
purchaseoffset by the change of vehicles of $17,000 compared to $3,000,000$3,869,089 in the redemption of short-term investments inand corporatethe securities,change $53,487of $14,490 for
the purchase of afixed related party convertible note, $5,000,000 for purchase of certificate of deposit, $5,000,000 for redemption of certificate
of deposit, purchase of research and development equipment for $3,016, and purchase of vehicles for $23,260.assets.
Cash provided by (used in) financing
activities during the year ended June 30, 20252026 was $2,156,096,$(231,047), compared to $781,295$2,156,096 for the year ended June 30, 2024.2025. The increasenet decrease in
cash provided by (used in) financing activities was primarily due to decreased proceeds from purchase agreements with investors for the sale of common stock, and an increase in netcash proceedsused fromfor the purchase agreements.of Series C preferred shares and cash used to fund a note receivable with a third-party with no similar transactions in the prior year.
Management
reviewed currently issued pronouncements during the year ended June 30, 2025,2026, and does not believe that any recently issued, but not yet
effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.
Pronouncements are disclosed in notes to the financial statements.
What changed in the latest 10-Q
Risk Factors
There are no material changes from the risk factors previously disclosed in our annual report on Form 10-K filed with the SEC on September 15, 2025.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
Largest changes
Results of Operations for thesee in full comparisonSixNine Months endedDecemberMarch 31,20252026 compared toSixNine Months EndedDecemberMarch 31,20242025
Other income and (expenses) for the three months endedsee in full comparisonDecemberMarch 31,20252026 were$170,213,$194,739, compared to$(2,213,120)$399,750 for the three months endedDecemberMarch 31,2024.2025. Theincreasedecrease in other income of$2,383,333$205,011 wasmainly athe result of an unrealized loss on the Company’sinvestment in TECO (Equity securities, related party on the Condensed Balance Sheets)investments in thepriorcurrent periodcomparedwhereastothenoCompanyunrealizedhadlossa gain on the Company’sinvestmentin TECOinvestments in thecurrentsameyearperiod of the prior year, a decrease in interest on investments offset byslight changesincreases ininvestmentotherincome,interestdividendincomeexpenses,dueandtounrealizedaandnoterealizedreceivablegain lossesenteredininto during the current periodcomparedwhereastothe Company had no note receivable in the same period of the prior year.
Cash provided by (used in) financing activities during thesee in full comparisonsixnine months endedDecemberMarch 31, 2026 and March 31, 2025and December 31, 2024was $(1,000,000668,123) and $2,156,096, respectively. The net decrease of$3,156,096$2,824,219 in cash provided by (used in) financing activities was due to decreased proceeds fromapurchaseagreementagreements enteredenteredwithan investorinvestors for the sale ofup to $45,000,000 ofcommonstock during the six months ended December 31, 2024 with no similar transactions in the six months ended December 31, 2025stock, and an increase in cash used for the purchase of Series C preferred shares and cash used to fund a note receivable with a third-party during thesixnine months endedDecemberMarch 31,20252026 with no similar transactions in thesixnine months endedDecemberMarch 31,2024.2025.
Cash used in operating activities wassee in full comparison$2,296,510$3,851,980 for thesixnine months endedDecemberMarch 31,2025,2026, compared to$1,568,936$2,970,810 for thesixnine months endedDecemberMarch 31,2024.2025. The net increaseincreaseof$727,574$881,170 in cash used in operating activities was due to a$2,459,674$2,663,230 decrease in the net loss, a change of$196,744$255,676 in prepaid expenses,expenses,a change in accrued expenses of$360,146$70,016,inaaccounts payable offset by $3,635,272$3,615,222 change in non-cash net expenses,$4,869and a $8,584 change in interest receivable offsetandby$103,997a change of $426,482 inaccruedaccountsexpenses.payable. In addition, the Company had revenues in the current periodcompanycompared to none in the prior period.
For the three months endedsee in full comparisonDecemberMarch 31,2025,2026, our net loss was$1,498,448,$1,534,383, compared to a net loss of$3,471,062$1,737,939 for the three months ended MarchDecember31,2024.2025. Theincreasedecrease in net loss of$1,972,614$203,556 wasprimarilydue toantheunrealizeddecreaselossinonoperating expenses offset by theCompany’s investment in TECO (Equity securities, related party on the Condensed Balance Sheets)decrease intheotherpriorincome/(expenses) asperiodexplainedcompared to no unrealized loss on the Company’s investment in TECO in the current year.above.
Operating expenses for thesee in full comparisonsixnine months endedDecemberMarch 31,20252026 were$3,593,056,$5,320,928, compared to$2,294,369$4,432,058 for thesixnine months endedDecemberMarch 31,2024.2025. TheThenet change of$1,298,687$890,126 in operating expenses consisted primarily ofan increaseincreases in research and developmentcostscosts, selling andgeneral,marketing expensesinand general and administrativeexpenses and in selling and marketing expenses due to increased efforts in operations.expenses.
Full comparison: every changed paragraph (18)
Unless the context otherwise
requires, references in this Form 10-Q to “we,” “us,” “our,” “SunHydrogen” or the “Company”
refer to
SunHydrogen, Inc.
Fair
value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where
it is practicable to estimate that value. As of SeptemberMarch 30,31, 2025, the amounts reported for cash, investment in affiliate, accrued interest
and other expenses, notes payables, and derivative liability approximate the fair value because of their short maturities.
Management
reviewed currently issued pronouncements during the sixnine months ended DecemberMarch 31, 2025,2026, and does not believe that any recently issued, but
but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed consolidated financial
statements. Pronouncements are disclosed in notes to the financial statements.
Results of Operations for the Three Months
ended DecemberMarch 31, 20252026 compared to Three Months Ended DecemberMarch 31, 20242025
Revenues for the three months ended DecemberMarch 31,
20252026 and 20242025 were $0.$0
Operating
expenses for the three months ended DecemberMarch 31, 20252026 were $1,668,661,$1,729,122, compared to $1,257,942$2,137,689 for the three months ended DecemberMarch 31, 2025.
2024. The net change of $41,719$408,567 in operating expenses consisted primarily of increasesdecreases in research and development costs,costs inand general and administrative
administrative expenses andoffset by increases in selling and marketing expenses due to increased efforts in operations.costs.
Other
income and (expenses) for the three months ended DecemberMarch 31, 20252026 were $170,213,$194,739, compared to $(2,213,120)$399,750 for the three months ended
December March 31, 2024.
2025. The increasedecrease in other income of $2,383,333$205,011 was mainly athe result of an unrealized loss on the Company’s investment
in TECO (Equity securities, related party on the Condensed Balance Sheets)investments in the prior current
period comparedwhereas tothe noCompany unrealizedhad lossa gain on the Company’s
investment in TECOinvestments in the currentsame yearperiod of the prior year, a decrease in interest
on investments offset by slight changesincreases in investmentother income,interest dividendincome expenses,due andto unrealizeda andnote realizedreceivable gain
lossesentered ininto during the current period comparedwhereas tothe
Company had no note receivable in the same period of the prior year.
For
the three months ended DecemberMarch 31, 2025,2026, our net loss was $1,498,448,$1,534,383, compared to a net loss of $3,471,062$1,737,939 for the three months ended March
December 31, 2024.2025. The increasedecrease in net loss of $1,972,614$203,556 was primarily due to anthe unrealizeddecrease lossin onoperating expenses offset by the Company’s investment in
TECO (Equity securities, related party on the Condensed Balance Sheets)decrease in theother priorincome/(expenses)
as periodexplained compared to no unrealized loss on the Company’s
investment in TECO in the current year.above.
Results of Operations for the SixNine Months ended
DecemberMarch 31, 20252026 compared to SixNine Months Ended DecemberMarch 31, 20242025
Revenues
for the sixnine months ended DecemberMarch 31,
2025 2026 were $1,250, compared to $0 for the sixnine months ended DecemberMarch 31, 2024.2025. The net change of $1,250
in revenue was due to the Company
providing consulting services to a related party during the sixnine months ended December 31, 2025 with
no similar consulting services provided
in the same period of the prior year.
Operating
expenses for the sixnine months ended DecemberMarch 31, 20252026 were $3,593,056,$5,320,928, compared to $2,294,369$4,432,058 for the sixnine months ended DecemberMarch 31, 2024.2025. The
The net change of $1,298,687$890,126 in operating expenses consisted primarily of an increaseincreases in research and development costscosts, selling and general,marketing
expenses in
and general and administrative expenses and in selling and marketing expenses due to increased efforts in operations.expenses.
Other
income and (expenses) for the sixnine months ended DecemberMarch 31, 20252026 were $533,580,$728,319, compared to $(3,223,5312,823,781) for the sixnine months ended DecemberMarch
31, 2024.2025. The increase in other income of $3,757,111$3,552,100 was primarily the result of an unrealized loss on the Company’s investment
in TECO (Equity
securities, related party on the Condensed Consolidated Balance Sheets) in the prior period compared to no unrealized loss on the Company’s
investment in TECO the current year partially offset by slight changes in investment income, dividend expense, and unrealized and realized gain
gain and losses.
For
the sixnine months ended DecemberMarch 31, 2025,2026, our net loss was $3,058,226,$4,592,609, compared to a net loss of $5,517,900$7,255,839 for the sixnine months ended DecemberMarch
31, 2024.2025. The decrease in net loss of $2,459,674$2,663,224 was primarily due to the unrealized loss on the Company’s investment in TECO (Equity
securities, related party on the Condensed Consolidated Balance Sheets) in the prior period compared to no unrealized loss on the Company’s
investment investment
in TECO the current period. In addition, the Company generated minimal revenues in the current period and none in the prior
year period
and had a large increase in operating expenses in the current period compared to the prior year period due to increased efforts
in operations.
As of DecemberMarch 31, 2025,2026, we had
had working capital of $33,569,593,$33,053,907, compared to $37,048,679 as of June 30, 2025. This decrease in working capital of $3,479,086$3,994,772 was primarily
due to a decrease in cash and prepaids offset by increases in prepaids, note receivable, interest receivable, short-term investments, and total current
liabilities.
Cash used in operating activities
was $2,296,510$3,851,980 for the sixnine months ended DecemberMarch 31, 2025,2026, compared to $1,568,936$2,970,810 for the sixnine months ended DecemberMarch 31, 2024.2025. The net increase
increase of $727,574$881,170 in cash used in operating activities was due to a $2,459,674$2,663,230 decrease in the net loss, a change of $196,744$255,676 in prepaid expenses,
expenses, a change in accrued expenses of $360,146$70,016, ina accounts payable offset by $3,635,272$3,615,222 change in non-cash net expenses, $4,869and a $8,584 change in interest receivable offset
andby $103,997a change of $426,482 in accruedaccounts expenses.payable. In addition, the Company had revenues in the current period companycompared to none in the prior
period.
Cash provided by (used) in
investing activities
during the sixnine months ended DecemberMarch 31, 2026 and March 31, 2025 and December 31, 2024 was $16,925,335$(17,033,385) and $0,$(6,030,113), respectively.
The net increase of $16,925,335
$11,003,272 in cash used in investing activities was due to the purchase of short-term investments offset by the redemption
of short-term investments
during the sixnine months ended DecemberMarch 31, 20252026 with no similar transactions in the sixnine months ended DecemberMarch 31, 2024.
2025.
Cash provided by (used in)
financing activities during the sixnine months ended DecemberMarch 31, 2026 and March 31, 2025 and December 31, 2024 was $(1,000,000668,123) and $2,156,096, respectively.
The net
decrease of $3,156,096$2,824,219 in cash provided by (used in) financing activities was due to decreased proceeds from a purchase agreementagreements entered
entered with an investorinvestors for the sale of up to $45,000,000 of common stock during the six months ended December 31, 2024 with no similar
transactions in the six months ended December 31, 2025stock, and an increase in cash used for the purchase of Series C preferred shares and cash used
to fund a note receivable with a third-party during
the sixnine months ended DecemberMarch 31, 20252026 with no similar transactions in the sixnine months
ended DecemberMarch 31, 2024.2025.
Our ability to continue as a going concern is dependent upon raising capital through financing transactions and future revenue. Our capital needs have primarily been met from the proceeds of private placements and registered offerings of our securities, as we have not generated any significant revenues to date.
HYSR insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding HYSR (13F)
None of the 59 investors we track reported a position in their latest 13F.